[PDF] academia.edu

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

F Eren, R Kurt, F Ermis, O Atug, N Imeryuz, Y Yilmaz - Clinical biochemistry, 2012 - Elsevier
F Eren, R Kurt, F Ermis, O Atug, N Imeryuz, Y Yilmaz
Clinical biochemistry, 2012•Elsevier
OBJECTIVES: We sought to determine whether serum concentrations of fibroblast growth
factor 19 (FGF19)–an ileum-derived enterokine which plays a role in the control of glucose
and lipid homeostasis–are altered in patients with biopsy-proven nonalcoholic fatty liver
disease (NAFLD). DESIGN AND METHODS: Serum levels of FGF19 were measured using
enzyme-linked immunosorbent assay in 91 patients with biopsy-proven NAFLD and 74
controls. RESULTS: FGF19 levels were significantly lower in patients with biopsy-proven …
OBJECTIVES
We sought to determine whether serum concentrations of fibroblast growth factor 19 (FGF19) – an ileum-derived enterokine which plays a role in the control of glucose and lipid homeostasis – are altered in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD).
DESIGN AND METHODS
Serum levels of FGF19 were measured using enzyme-linked immunosorbent assay in 91 patients with biopsy-proven NAFLD and 74 controls.
RESULTS
FGF19 levels were significantly lower in patients with biopsy-proven NAFLD (median: 130pg/mL) than in controls (median: 210pg/mL, P<0.001). Serum FGF19 levels were significantly but modestly associated with hepatocyte ballooning scores in univariate analysis (r=−0.25, P<0.05) but not after adjustment for potential confounders (β=−0.18; t=1.78, P=0.08).
CONCLUSIONS
This pilot study suggests that serum FGF19 levels are decreased in patients with NAFLD but are not independently associated with liver histology findings.
Elsevier
Show moreShow less
Save Cite Cited by 61 Related articles All 9 versions